Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neuroimmunomodulation

Guidelines for Authors
www.karger.com/nim_guidelines

Aims and Scope
Submission
Conditions
Rapid Communications
Plagiarism Policy
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Page Charges
Electronic Proofs
Reprints



Aims and Scope

The rapidly expanding area of research known as neuroimmunomodulation explores the way in which the nervous system interacts with the immune system via neural, hormonal, and paracrine actions.

Encompassing both basic and clinical research, 'Neuroimmunomodulation' reports on all aspects of these interactions. Basic investigations consider all neural and humoral interactions from molecular genetics through cell regulation to integrative systems of the body. The journal also aims to clarify the basic mechanisms involved in the pathogenesis of the CNS pathology in AIDS patients and in various neurodegenerative diseases.

Although primarily devoted to research articles, timely reviews will be published on a regular basis.

To ensure high quality, all papers will be reviewed by at least two referees, with every effort made to maintain a short publication time.




Submission

Only original papers written in English are considered and should be submitted online.

Authors are asked to suggest three to four potential reviewers for their manuscript. These experts on the topic of the article should not be from the same institution as the author(s). The names and the full postal and e-mail addresses of potential reviewers should be submitted with each article. Editors will consider these suggestions but are not bound by them.

Should you experience any problems with your submission, please contact

Andrea Zumbrunn
Editorial Office 'Neuroimmunomodulation'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1360
Fax +41 61 306 1434
nim@karger.com




Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Neuroimmunomodulation’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

For legal reasons, we must receive your 'Submission Statement' with your original (hand-written) signature. Please download, print, sign and either fax or scan it to make it legally binding.

Most reviews are solicited by the editors. Unsolicited reviews may also be considered, but authors should send a brief proposal to the editorial office, summarizing the topic of the proposed review and 4–5 key references.

Manuscripts should be written in English. They should contain unpublished results of research work, and should be as concise as possible.

The following presentation is recommended: Abstract, Introductory statement on the purpose of the studies, Materials and Methods, Results, Discussion, and References.

Commonly accepted abbreviations (e.g. ACTH, TSH, DNA) may be used throughout the text and tables, but a definition should be provided the first time each abbreviation is used. Please limit abbreviations to those in common use, and avoid other abbreviations and acronyms.

Contributions will generally be printed in order of acceptance for publication.

All studies based on experiments/trials conducted with humans or animals must have been approved by the author's institutional review board. This board's ethical approval must be declared within the methods section. All patients referred to in human studies should be identified by numbers or aliases, not by their real names, and must have provided informed consent prior to their inclusion in the study. All clinical investigations must have been conducted according to Declaration of Helsinki principles. Manuscripts failing to comply with these requirements will not be considered for publication.

Papers that do not meet these criteria will not be accepted for publication.




Rapid Communications

Manuscripts intended for rapid communication must present new findings of sufficient importance to justify their accelerated appearance. Double-spaced manuscripts cannot exceed 7 pages, including figures, tables and references; longer manuscripts will be returned. Rapid communications are subject to the usual editorial review and are published within 2 months following acceptance. Proofs are sent to the Editors and to the authors.




Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).




Arrangement

Title page: The first page of each paper should carry the title, the authors' full first and last names, and the name of the institute or department where the authors conducted their research work.

In addition, the following should be put on the title page:
1. A short title for use as a running head;
2. A list of 3–9 key words that reflect the content of the paper;
3. The name and complete mailing address as well as phone and fax numbers as well as e-mail address of the individual to whom correspondence, proofs, and requests for reprints should be addressed.

Abstract: Each paper needs an abstract of up to 250 words.
Abstracts for Original Papers should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).
The words used in the subheadings of the Abstract are not included in the 250 words of the Abstract.

Footnotes: Avoid footnotes if at all possible. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.

Acknowledgments, including, where relevant, credit to the sources of grant support, should be placed before the references.

Tables and illustrations: Tables (numbered in arabic numerals) should be prepared on separate sheets, and each should have a suitable heading. Illustrations should be numbered in Arabic numerals and legends for the figures should be submitted on a separate page. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 181 x 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author's name, and ‘top’ with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1200 dpi.




Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.000 per page.




References

In the text identify references by Arabic numerals [in square brackets]. Papers that have been submitted to a journal but are not yet accepted should not be listed in the bibliography, but the data in them can be referred to in the text as unpublished observations. If details of methods are only available in papers that are ‘in press’, copies of the papers should be included with the manuscript submitted to ‘Neuroimmunomodulation’, so that the editorial referees can have adequate information to judge the manuscript. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of all the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

(a) Papers published in periodicals: Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. Int Arch Allergy Immunol 1997;112:191–195.

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.

(d) Edited books: Parren PWHI, Burton DR: Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy; in Capra JD (ed): Antibody Engineering. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18–56.

(e) Papers published in electronic format: Black CA: Delayed type hypersensitivity. Current theories with a historic perspective. Dermatol Online J 1999;5:7. http://dermatology.cdlib.org/DOJvol5num1.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.




Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org




Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.



Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.


Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.


Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.




Page Charges

There are no page charges for papers of 5 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 15 manuscript pages (including tables, illustrations and references).




Electronic Proofs

Unless indicated otherwise, proofs will be e-mailed to the corresponding author.




Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.